Total costs related to goods produced and sold during the reporting period.

Name:	us-gaap_CostOfGoodsSold
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=98514028&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

+ Details

Name:	us-gaap_Depreciation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h)(1)(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_NumberOfOperatingSegments
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingExpenses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The net result for the period of deducting operating expenses from operating revenues.

+ References

No definition available.

+ Details

Name:	us-gaap_OperatingIncomeLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 32
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=82859839&loc=SL82860478-203043

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130539-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingInformationLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 330
-SubTopic 10
-Section 30
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311

+ Details

Name:	us-gaap_SellingGeneralAndAdministrativeExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.

+ References

+ Details

Name:	us-gaap_ShareBasedCompensation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=cdxs_CoreSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=cdxs_BiotherapeuticSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cdxs_ProductSalesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=cdxs_SegmentOperatingExpenseAllocationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Segment, Geographical and Other Revenue Information - Segment Reporting (Details) $ in Thousands	3 Months Ended				6 Months Ended		12 Months Ended
	Jun. 30, 2018 USD ($)	Mar. 31, 2018 USD ($)	Jun. 30, 2017 USD ($)	Mar. 31, 2017 USD ($)	Jun. 30, 2018 USD ($) segment	Jun. 30, 2017 USD ($)	Dec. 31, 2017 segment
Segment Reporting Information [Line Items]
Number of operating segments \| segment					2		1
Revenue	$ 13,538		$ 10,347		$ 27,580	$ 18,317
Cost of product revenue	2,611		3,790		6,436	6,792
Research and development	7,370		6,348		14,548	12,187
Selling, general and administrative	7,395		6,546		15,141	13,152
Total segment costs and operating expenses	17,376		16,684		36,125	32,131
Income (loss) from operations	(3,838)		(6,337)		(8,545)	(13,814)
Loss before income taxes	(3,746)		(6,322)		(8,442)	(13,758)
Stock-based compensation	2,457		1,711		4,437	3,379
Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Revenue	11,165		10,347		21,894	18,317
Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Revenue	2,373		0		5,686	0
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	13,538		10,347		27,580	18,317
Cost of product revenue	2,611		3,790		6,436	6,792
Research and development	7,166		6,172		14,164	11,832
Selling, general and administrative	2,033		1,777		4,275	3,589
Total segment costs and operating expenses	11,810		11,739		24,875	22,213
Income (loss) from operations	1,728		(1,392)		2,705	(3,896)
Stock-based compensation	851		481		1,472	889
Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Revenue	11,165		10,347		21,894	18,317
Cost of product revenue	2,611		3,790		6,436	6,792
Research and development	4,724		4,023		9,790	8,172
Selling, general and administrative	1,729		1,777		3,825	3,589
Total segment costs and operating expenses	9,064		9,590		20,051	18,553
Income (loss) from operations	2,101		757		1,843	(236)
Stock-based compensation	768		434		1,326	789
Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Revenue	2,373		0		5,686	0
Cost of product revenue	0		0		0	0
Research and development	2,442		2,149		4,374	3,660
Selling, general and administrative	304		0		450	0
Total segment costs and operating expenses	2,746		2,149		4,824	3,660
Income (loss) from operations	(373)		(2,149)		862	(3,660)
Stock-based compensation	83		47		146	100
Corporate [Member]
Segment Reporting Information [Line Items]
Total segment costs and operating expenses	(5,209)		(4,702)		(10,644)	(9,308)
Depreciation and amortization	(265)		(228)		(503)	(554)
Product Sales [Member]
Segment Reporting Information [Line Items]
Revenue	3,723		6,600		9,886	12,186
Product Sales [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Revenue	3,723		6,600		9,886	12,186
Product Sales [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Revenue	0		0		0	0
Product Sales [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	3,723		6,600		9,886	12,186
Product Sales [Member] \| Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Revenue	3,723		6,600		9,886	12,186
Product Sales [Member] \| Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Revenue	0		0		0	0
Research and Development Revenue [Member]
Segment Reporting Information [Line Items]
Revenue	9,815		3,747		17,694	6,131
Research and Development Revenue [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Revenue	7,442		3,747		12,008	6,131
Research and Development Revenue [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Revenue	2,373		0		5,686	0
Research and Development Revenue [Member] \| Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	9,815		3,747		17,694	6,131
Research and Development Revenue [Member] \| Operating Segments [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Revenue	7,442		3,747		12,008	6,131
Research and Development Revenue [Member] \| Operating Segments [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Revenue	$ 2,373		$ 0		$ 5,686	$ 0
Segment Operating Expense Allocation [Member] \| Performance Enzymes [Member]
Segment Reporting Information [Line Items]
Research and development		$ (300)
Segment Operating Expense Allocation [Member] \| Novel Biotherapeutics [Member]
Segment Reporting Information [Line Items]
Research and development				$ (100)